Mouse Monoclonal Neuropilin-1 Antibody

Neuropilin-1 (NRP1) is a transmembrane glycoprotein that functions as a co-receptor for multiple signaling pathways, primarily binding to class 3 semaphorins (SEMA3) and vascular endothelial growth factors (VEGFs). It plays critical roles in angiogenesis, axon guidance, and immune regulation by modulating cellular signaling and receptor internalization. NRP1 is overexpressed in various cancers, endothelial cells, and certain immune cells, making it a promising therapeutic target. Antibodies targeting NRP1 are designed to block its interaction with ligands like VEGF-A or SEMA3. thereby inhibiting downstream pathways involved in tumor progression, vascular remodeling, or immune evasion. These antibodies have shown potential in preclinical studies to suppress tumor growth, metastasis, and angiogenesis. Additionally, NRP1 antibodies are explored in immune-oncology due to their ability to modulate T-cell activity and dendritic cell function. However, challenges remain in optimizing specificity and minimizing off-target effects, as NRP1 participates in diverse physiological processes. Current research focuses on developing bispecific antibodies or combination therapies to enhance efficacy. Understanding NRP1's structural domains and ligand-binding interfaces has been pivotal in engineering therapeutic antibodies with improved affinity and functional blockade.